CAH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardinal Health Inc (CAH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the recent price drop, the company's strong financial performance, positive analyst sentiment, and a stable healthcare sector make it a solid choice for long-term growth. The absence of significant insider or hedge fund trading trends and no recent Congress trading data does not raise any red flags.
The technical indicators show mixed signals. The MACD is negative and expanding, indicating bearish momentum, while the RSI is neutral at 25.189. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a long-term upward trend. The stock is currently trading near a key support level (S1: 218.171), which may provide a good entry point for long-term investors.
Strong Q2 financial performance with revenue up 18.75% YoY, net income up 16.75% YoY, and EPS up 19.39% YoY.
Positive analyst sentiment with multiple price target increases, most recently to $
Jim Cramer's Charitable Trust purchasing 170 shares of CAH, reflecting confidence in the company's prospects.
Healthcare sector resilience amid geopolitical tensions.
Recent price decline of -3.21% in the regular market session.
Bearish MACD indicator and high implied volatility, suggesting potential short-term price fluctuations.
Broader market weakness with the S&P 500 down -0.56%.
Cardinal Health reported strong Q2 2026 financial results. Revenue increased by 18.75% YoY to $65.63 billion, net income rose by 16.75% YoY to $467 million, and EPS grew by 19.39% YoY to $1.97. Gross margin improved to 3.52%, up 3.83% YoY, indicating efficient cost management and profitability.
Analysts are overwhelmingly positive on CAH, with multiple firms raising price targets recently. The highest target is $260, reflecting confidence in the company's growth trajectory. Analysts highlight strength in the Pharmaceutical and Specialty segments and consistent execution as key drivers of future performance.
